What to Expect in 2026
Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater.
In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting the latest trailblazing innovation, from novel interventions for disease modification, encompassing protein aggregation, neuroinflammation, metabolic pathways, neurotrophic factors and more to the groundbreaking progress in p-tau217 and fluid-based biomarkers.
The 2026 program is built to explore disease progression, modification and prodromal intervention, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need.
Unmissable Event Highlights
Next-Generation Modelling
Collaborate with fellow industry professionals in 2 deep dive workshops decoding protein aggregation in vitro and reimaging translational validity in vivo for enhanced predictive power.
The Future of Phlebotomy for Less Invasive Diagnosis
Focus in on the most recent progress from blood-based biomarkers to emerging targets beyond p-tau & αSynuclein on the fluid biomarker seminar day.
Real-World Therapeutic Experience to Re-Prioritise Pipelines
Hear from a physician panel and a patient living with Parkinson’s Disease to redefine therapeutic success and build meaningful clinical endpoints for improved uptake.
From Setbacks to Solutions
Build on the learnings from Lecanemab and Donanemab to inform novel therapeutics pathways and side effect considerations.Â
Divide & Conquer
Discovery & Preclinical Track
This track highlights the latest science driving novel targets and translational confidence in Alzheimer’s and Parkinson’s drug development. Attendees will explore in vitro and in vivo models, omics analysis, and biomarker assay platforms that enable more predictive decision-making at the earliest stages. The focus is on turning mechanistic insights into IND-ready packages by sharpening links between preclinical signals, fluid biomarkers, and imaging endpoints.
Features:Â
- Innovative models replicating protein aggregation, neuroinflammation, and genetic risk modifiersÂ
- Next-generation plasma assays, digital endpoints, and quantitative biomarkers to predict disease progressionÂ
- Strategies for de-risking translation through high-throughput, reproducible, and human-relevant systemsÂ
Speaking Companies Include:
Bristol Myers Squibb, Eli Lilly, Gismo Therapeutics, Inflammasome Therapeutics, Alexion Pharmaceuticals
Clinical & Regulatory Track
This track captures the clinical and regulatory journey, showcasing late-stage data, regulatory frameworks, and market access strategies that shape the future of disease-modifying therapies. Sessions will address trial design innovations, digital endpoints, and patient-centric measures that strengthen regulatory dossiers and payer confidence.
Features:
- Latest Phase II/III trial data across Alzheimer’s and Parkinson’s disease pipelines
- Insights on companion diagnostics, adaptive platform trials, and digital biomarkers
- Regulatory perspectives and case studies on market adoption and reimbursement
Speaking Companies Include:
Alzheon, Roche, Takeda, Acumen Pharmaceuticals
Explore the Full Event Guide
- 2 deep dive workshops into in vivo and in vitro modelling advancements
- Seminar day on fluid-based biomarker innovation
- 30+ expert speakers including industry leaders, academic KOLs and patient voices
- Multiple tracks of content spanning discovery, preclinical, clinical and regulatory
- 10+ hours dedicated networking time over 3 days
Attending Companies Include
Brand New Companies for 2026
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive regulatory insights during 3 jam-packed days of interactive workshops, roundtables, panel discussions and data driven content.
Partner With Us
Position yourself alongside other leading solution providers.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.